In this scenario, customized medicine has brought successful outcomes in drug selection for lung cancer patients with NSCLC based on the paradigms of their molecular profiles, specifically those with positive genetic alterations in EGFR, ALK, ROS-1, HER2, BRAF, MET, and RET genes [13,110]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.